Innate Pharma SA: Innate Pharma Reports First Half 2022 Fina

Monalizumab and IPH5201 developed in collaboration with AstraZeneca advanced into Phase 3 and 2 clinical trials in lung cancer, triggering $55M in milestone payments Second preclinical asset

Related Keywords

United States , Russia , France , Ukraine , French , Ukrainian , American , Patrick Langlois , Enregistrement Universel , Mondher Mahjoubi , Bristol Myers Squibb , Sally Bennett , Henry Wheeler , Institut Paoli Calmettes , Novo Nordisk , Supervisory Board Of The Company On , Company Orega Biotech , Treatment Of Cancer Cutaneous Lymphoma Tumours Group , Audit Committee , Nasdaq , Company Annual Report On Form , Company On , Astrazeneca , European Union , Board Of The Company On , Data Monitoring Committee , European Organisation For Research , Exchange Commission , French Financial Markets Authority , American Association For Cancer Research , Lymphoma Study Association , European Society For Medical Oncology , Euronext , Euronext Paris , Chief Executive Officer , Innate Pharma , European Organisation , Cancer Cutaneous Lymphoma Tumours Group , Company Sponsored Phase , European Society , Medical Oncology , Engager Therapeutics , Astrazeneca Sponsored Phase , Clinical Oncologyon April , Clinical Oncology , American Association , Cancer Research , Annual Meeting , Independent Data Monitoring Committee , Programs Option , American Depositary Shares , Supervisory Board Meeting , Supervisory Board , Orega Biotech , Natural Killer , Private Securities Litigation Reform Act , Risk Factors , Universal Registration Document , Annual Report , Condensed Consolidated Statements , Financial Position , Cash Flow , Sarbanes Oxley Act , Lumoxiti Agreement , Transition Agreement , Settlement Amount , State Guaranteed Loans , Statutory Auditors , Executive Board , Des March , Yinnate , Dharma , Reports , First , Calf , 022 , Financial , Results , Business , Update ,